Firm advances programs and funds operations to late 2027
Perspective Therapeutics, Inc. (NYSE American: CATX) announced 2Q 2026 results, advancing programs like VMT-α-NET toward a Phase 3 study while reporting over $237 million in cash to fund operations into late 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day